PMID- 32051805
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2168-8184 (Print)
IS  - 2168-8184 (Electronic)
IS  - 2168-8184 (Linking)
VI  - 12
IP  - 2
DP  - 2020 Feb 10
TI  - Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and 
      Who Benefits?
PG  - e6934
LID - 10.7759/cureus.6934 [doi]
LID - e6934
AB  - INTRODUCTION: Unprovoked venous thromboembolism (uVTE) may be the first 
      manifestation of cancer. The main objectives of this study were to compare 
      limited screening (LS) and extended screening (ES) and to make a protocol to 
      approach these patients. METHODS: This is a retrospective, unicentric 
      observational study that included 245 patients with venous thromboembolism (VTE) 
      admitted to an Internal Medicine Service for five years. The incidence of cancer 
      and mortality during hospitalization, and at one and three years after admission 
      were calculated in both LS and ES groups and compared. RESULTS: Of the 245 
      patients with VTE, 59 (24.1%) had uVTE: 35 (59.3%) were submitted to LS and 24 
      (40.7%) to ES, with 10 (4.1%) diagnosis of cancer. In the following three years, 
      10 more patients were diagnosed. There were no statistically significant 
      differences in inpatient diagnosis rates (8.6% vs. 4.2%; p=0.51) or in-hospital 
      mortality (2.9% vs. 4.2%; p=0.79) or mortality at one year (8.6% vs. 8.3%; 
      p=0.97) and three years (20.0% vs. 20.8%; p = 0.94) between LS and ES groups 
      respectively. The Computerized Registry of Patients with Venous Thromboembolism 
      (RIETE) score was equal or superior to 3 in 69.5% (N=41) of the population with 
      uVTE. DISCUSSION: The results of our study are consistent with the literature; 
      there are no differences between screenings, as the difference in the number of 
      diagnoses does not reflect on mortality. CONCLUSION: There were no statistically 
      significant differences between the two types of screening in this population. We 
      suggest a protocol that includes the RIETE score to better select the patients 
      who might benefit the most from an ES.
CI  - Copyright (c) 2020, Ferreira et al.
FAU - Ferreira, Filipa
AU  - Ferreira F
AD  - Medical Oncology, Centro Hospitalar de Lisboa Ocidental, Lisbon, PRT.
FAU - Pereira, Jose
AU  - Pereira J
AD  - Medical Oncology, Centro Hospitalar de Lisboa Ocidental, Lisbon, PRT.
FAU - Lynce, Ana
AU  - Lynce A
AD  - Internal Medicine, Centro Hospitalar de Lisboa Ocidental, Lisbon, PRT.
FAU - Nunes Marques, Jose
AU  - Nunes Marques J
AD  - Medical Oncology, Centro Hospitalar de Lisboa Ocidental, Lisbon, PRT.
FAU - Martins, Ana
AU  - Martins A
AD  - Medical Oncology, Centro Hospitalar de Lisboa Ocidental, Lisbon, PRT.
LA  - eng
PT  - Journal Article
DEP - 20200210
PL  - United States
TA  - Cureus
JT  - Cureus
JID - 101596737
PMC - PMC7011576
OTO - NOTNLM
OT  - cancer
OT  - cancer screening
OT  - mortality
OT  - thromboembolism
OT  - unprovoked thromboembolism
COIS- The authors have declared that no competing interests exist.
EDAT- 2020/02/14 06:00
MHDA- 2020/02/14 06:01
PMCR- 2020/02/10
CRDT- 2020/02/14 06:00
PHST- 2020/02/14 06:00 [entrez]
PHST- 2020/02/14 06:00 [pubmed]
PHST- 2020/02/14 06:01 [medline]
PHST- 2020/02/10 00:00 [pmc-release]
AID - 10.7759/cureus.6934 [doi]
PST - epublish
SO  - Cureus. 2020 Feb 10;12(2):e6934. doi: 10.7759/cureus.6934.